title: C-MOPP/ABV yields good results in a public hospital population with Hodgkin disease in Brazil.
abstract: BACKGROUND
  Over the last 15 years, a number of combination chemotherapy regimens have been reported to induce more than 80% complete remissions (CR) in patients with advanced Hodgkin disease (HD). Almost all such studies have been conducted in large institutions from North America and Europe. It remains to be proven, however, that those regimens are equally effective for the larger population of patients with HD who live in very different social conditions in third-world countries.
  
  
  METHODS
  Fifty-nine patients with advanced-stage or early bulky HD were treated in two public hospitals with the C-MOPP/ABV hybrid program, in which cyclophosphamide was substituted for mechlorethamine.
  
  
  RESULTS
  The median number of cycles administered was six, and the median follow-up was 32 months. Fifty patients (85%) reached a CR. The actuarial failure-free survival (FFS) rate was 69%, and the actuarial overall survival rate was 78% at 68 months. The only significant prognostic factor that predicted for improved FFS rate was the absence of B symptoms (P = 0.02). Overall survival was better for patients who reached a CR (P = 0.0003) and those with no systemic symptoms (P = 0.007). Toxic effects were moderate, with one treatment-related death and six episodes of serious infection.
  
  
  CONCLUSIONS
  The target population consisted of lower-class Brazilians, many living in poor social conditions. Nevertheless, these results compare equitably with other results reported in the literature. C-MOPP/ABV is an adequate treatment for HD in third-world populations.
authors.affiliation: Hematology Service, University Hospital, Federal University of Rio de Janeiro, Brazil.
authors.forename: N
authors.initials: N
authors.lastname: Spector
authors.forename: M A
authors.initials: MA
authors.lastname: Costa
authors.forename: W
authors.initials: W
authors.lastname: Pulcheri
authors.forename: R C
authors.initials: RC
authors.lastname: Salgado
authors.forename: M
authors.initials: M
authors.lastname: Nucci
authors.forename: C A
authors.initials: CA
authors.lastname: Andrade
authors.forename: J C
authors.initials: JC
authors.lastname: de Morais
authors.forename: O
authors.initials: O
authors.lastname: de Castro
authors.forename: A F
authors.initials: AF
authors.lastname: Scaletsky
authors.forename: E
authors.initials: E
authors.lastname: Brabo
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D001938:Brazil / Q000453:epidemiology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006779:Hospitals, Public; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone